Elanco Animal Health (NYSE:ELAN) had its price objective hoisted by Barclays from $25.00 to $35.00 in a report released on Monday morning, The Fly reports. The brokerage currently has an overweight rating on the stock.
ELAN has been the subject of several other reports. Citigroup increased their price objective on Elanco Animal Health from $27.00 to $32.00 and gave the company a buy rating in a report on Thursday, October 1st. Cleveland Research downgraded Elanco Animal Health from a neutral rating to an underperform rating and set a $19.00 price target for the company. in a report on Monday, July 27th. The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research note on Tuesday, August 4th. They issued a buy rating and a $26.50 price objective on the stock. Zacks Investment Research cut shares of Elanco Animal Health from a hold rating to a sell rating in a research note on Tuesday, October 20th. Finally, Raymond James reaffirmed a hold rating on shares of Elanco Animal Health in a report on Wednesday, October 7th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. Elanco Animal Health has an average rating of Hold and a consensus target price of $28.50.
ELAN stock opened at $31.51 on Monday. The company has a market capitalization of $12.57 billion, a P/E ratio of -126.04, a PEG ratio of 6.22 and a beta of 1.04. Elanco Animal Health has a twelve month low of $15.17 and a twelve month high of $34.09. The business has a 50 day simple moving average of $29.22 and a 200-day simple moving average of $24.81. The company has a current ratio of 3.82, a quick ratio of 2.54 and a debt-to-equity ratio of 0.31.
Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.07. The business had revenue of $586.30 million during the quarter, compared to the consensus estimate of $555.84 million. Elanco Animal Health had a positive return on equity of 4.68% and a negative net margin of 3.63%. Research analysts predict that Elanco Animal Health will post 0.54 EPS for the current fiscal year.
In related news, insider Todd S. Young bought 7,000 shares of the stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $23.91 per share, for a total transaction of $167,370.00. Following the completion of the transaction, the insider now owns 41,513 shares of the company’s stock, valued at approximately $992,575.83. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John P. Bilbrey bought 9,580 shares of the stock in a transaction on Wednesday, August 19th. The shares were bought at an average price of $26.20 per share, for a total transaction of $250,996.00. Following the completion of the transaction, the director now directly owns 8,016 shares of the company’s stock, valued at approximately $210,019.20. The disclosure for this purchase can be found here. Insiders have acquired 38,580 shares of company stock worth $1,021,586 over the last 90 days. 0.12% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in shares of Elanco Animal Health by 25.4% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 4,495,075 shares of the company’s stock valued at $96,059,000 after purchasing an additional 910,087 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Elanco Animal Health by 16.4% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 63,300 shares of the company’s stock valued at $1,417,000 after purchasing an additional 8,900 shares in the last quarter. Holocene Advisors LP purchased a new stake in shares of Elanco Animal Health in the second quarter valued at about $29,057,000. Morgan Stanley lifted its holdings in shares of Elanco Animal Health by 31.4% in the first quarter. Morgan Stanley now owns 549,482 shares of the company’s stock valued at $12,302,000 after purchasing an additional 131,196 shares in the last quarter. Finally, IFM Investors Pty Ltd lifted its holdings in shares of Elanco Animal Health by 10.2% in the third quarter. IFM Investors Pty Ltd now owns 32,055 shares of the company’s stock valued at $895,000 after purchasing an additional 2,963 shares in the last quarter. 98.22% of the stock is currently owned by institutional investors.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals. It offers companion animal disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production.
Further Reading: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.